Kornimate/medical-research-clean huggingface dataset:
online educational tool for caregivers of pediatric oncology patients

Conditions: Caregiver Burden; Care Giving Burden; Pediatric Cancer

Summary: the goal of this study is to assess the feasibility of using a game-based tool for caregivers of pediatric oncology patients to increase caregiver knowledge about supportive care for oncology patients while simultaneously reducing caregiver anxiety.


Eligibility criteria:
inclusion criteria: * caregiver of a pediatric cancer patient who was recently diagnosed with cancer, including all pediatric malignancies. multiple caregivers can be enrolled. caregiver is defined as a person who is responsible for the direct care, protection, and supervision of the pediatric cancer patient. in this context, a caregiver is not required to be the parent or legal guardian. * caregivers must have completed oncology nursing education either in the inpatient or outpatient setting. * inpatient setting: before discharge from hospital after nursing education * outpatient setting: within 15 days of discharge from the inpatient setting after nursing education or within 21 days of nursing education if diagnosis made in the outpatient setting exclusion criteria: * if less than 18 years of age * unable to utilize the electronic tool, complete the pre/post questionnaires and anxiety scale due to reading abilities, intellectual or physical disabilities. * cared for another child with cancer or secondary diagnosis

Keywords: caregiver pediatric oncology
metabolomic profiling in adolescents with obesity and diabetes

Conditions: Metabolomics; Obesity; Diabetes; Diabetic Nephropathies

Summary: the purpose of this study is to identify unique metabolite signatures associated with the development of type 2 diabetes and diabetic kidney disease in children. we have a sub-study, with the purpose to validate the presence of a genetic marker (dennd1a) in the urine of adolescent females with polycystic ovarian syndrome.


Eligibility criteria:
inclusion criteria: * age of 13-19 years * gender: male and female * ethnic background: any * obesity will be defined as bmi \>95th percentile for age/gender * diagnosis of diabetes will be defined by current american diabetes association criteria * diabetes duration \< 2.5 years * absence of pancreatic autoimmunity (gad65 and ica512 and insulin autoantibody) * adult caregiver willing to actively support study participation * signed parental informed consent form and adolescent assent form * for pcos substudy, the diagnosis of pcos will be defined according to the 1990 us national institute of health (nih) criteria (oligomenorrhea, clinical or biochemical signs of hyperandrogenism, and exclusion of other known disorders) exclusion criteria: * creatinine clearance \<60 ml/min (calculated from estimated gfr) * other significant organ system illness or condition (including psychiatric or developmental disorder) that, in the opinion of the investigator, would prevent participation. * for pcos substudy, use of medications that effect androgen levels in the blood (i.e. oral contraceptive pills, or metformin) for the last 3 months prior to enrollment
the efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment

Conditions: Osteoporosis

Summary: the efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment

we compare the effect of risedronate with placebo in bone mineral density changes in patients receiving high dose corticosteroids for their underlying diseases

Eligibility criteria:
inclusion criteria: 1. patients with various medical conditions who require high dose glucocorticoid treatment: (1) pulse methylprednisolone; (2) oral prednisolone (\>=0.8mg/kg/day) or equivalent for at least 6 weeks. 2. age\>=18 years and \<75 years. exclusion criteria: 1. pregnant or lactating women. 2. uncorrected hypocalcemia. 3. history of esophageal stricture. 4. previous intolerance or hypersenstivity to biphosphonates.

Keywords: corticosteroids, bone mineral, risedronate, bisphosphonate
non steroidal antiinflammatory drugs influence on heal of distal radius fracture

Conditions: Forearm Fracture

Summary: it is believed, that non steroidal antiinflammatory drug (nsaid) drugs slows bone healing, but the knowledge is based only on animal studies, and the results are automatically raised for the people. many patients with bone fracture must therefore avoid the formerly so popular and good painkillers, although no clinical trial evidence is, that this medicine is really harmful for patients with fractures. the purpose of this study is to investigate whether these drugs slows bone healing, and what the relationship is between various bone studies - dexa scanning, biochemical bone marker tests, radiographic controls and tissue examination of newly formed bone under a microscope. how sensitive and specific, each of the above study methods? if they are just as sensitive, the cheapest of them recommended as a routine investigation on suspicion of bone effects. furthermore, to compare the benefit (pain-relieving effect, influence on rehabilitation) of these drugs and their possible harmful side effects (affected and delayed bone healing). the expectation is that the study may contribute to increased knowledge about nsaids effect do pain management, rehabilitation and the entire treatment process significantly easier and safer, so that patients recover faster and return to usual activities.


Eligibility criteria:
inclusion criteria: * written acceptance to participate in the study * immobilisation or reposition or surgery demanding colles fracture (which needs to be fixed with external fixation). exclusion criteria: * age - younger than 50 years or older than 80 years * treatment with prednisolon * nsaids - treatment * previous fracture or surgery at the wrist * lack of mental and physical capacity to follow studies' instructions * lack of informed consent * other diseases can affect bone substance (oncology, endocrine diseases) * medical contraindications to nsaids use * smoking, alcohol consumption of more than 14 drinks per week * secondary dislocation of fracture also apply as exclusion criterion.

Keywords: nsaid bone fracture heal
hearing results and post surgical outcomes using amniotic membrane allograft vs. fascia for tympanoplasty

Conditions: Tympanic Membrane Perforation

Summary: the trial seeks to provide evidence that the skye activebarrier provides similar surgical and functional outcomes as fascia when used for tympanoplasties while offering benefits including reduced operative time, better patient satisfaction, and fewer complications.

a prospective randomized controlled trial will be conducted. eligible patients will be identified, recruited and randomized to receive either repair using the standard fascia graft or repair using the skye activebarrier. subjects will undergo a preoperative evaluation followed by tm repair and subsequent regular office visits to assess functional outcomes, complications, and satisfaction. patients will be blinded to the substrate used for their repair. as there are two different approaches for a tympanoplasty (through the ear canal or incision behind the ear) based on the subject's ear anatomy and location of the perforation, a sham surgery will not be necessary to disguise which graft is received. at follow up visits, photos may be taken of patients' tms and these photos will be evaluated for healing by an otologist who did not conduct the surgery in a blinded fashion. at the 1 year follow up appointment, subjects will be told which substrate they received and at the study's conclusion subjects will notified about the study's findings.

Eligibility criteria:
inclusion criteria: 1. presence of a tympanic membrane perforation 2. patient at pi's clinic exclusion criteria: 1. presence of cholesteatoma 2. prior surgery on the same-sided tm or middle ear 3. ossicular chain abnormalities 4. congenital deformities involving the middle ear or eustachian tube 5. refusal to undergo surgery

Keywords: tympanic membrane perforation
oxidative stress and bisphenol a (bpa) impact with polycystic ovary syndrome (pcos)

Conditions: Oxidative Stress; Endocrine Disrupting Chemicals; Polycystic Ovary Syndrome

Summary: both oxidative stress and bisphenol a (bpa) had been associated with polycystic ovary syndrome (pcos). bpa, one of endocrine-disrupting chemicals (edcs), is an environmental estrogen used in the synthesis of plastics, is a "high-volume production" chemical with widespread human exposure. bpa was been reported in several female reproductive disturbance. however, the pathological pathway of bpa impact on female reproductive system had not been well-understood. reactive oxygen species (ros) have a role in the modulation of gamete quality and gamete interaction. persistent and elevated generation of ros leads to a disturbance of redox potential that in turn causes oxidative stress (os). the first part of the investigators study is aim to evaluate the oxidative stress impact on the biochemical parameters in women with pcos; the secondary part of the investigators study is to investigate the bpa on the clinical and biochemical of women with pcos; finally, the investigators plan to test the hypothesis that bpa might increase oxidative stress and then elevated ros in women with menstrual disturbance, furthermore, the role of oxidative stress and bpa impact on insulin resistance and metabolic disturbance will be also investigated. study and control cases will be included. serum total oxidant status (tos), total antioxidant status (tas), bisphenol a (bpa), and clinical/biochemical parameters will be obtained for all cases. oxidative stress and bpa will be evaluated with all clinical/biochemical parameters for all subjects.


Eligibility criteria:
inclusion criteria: 1. normal health control 2. women with reproductive endocrine disturbance menstrual irregularity, and/or polycystic ovary syndrome. exclusion criteria: * the following subjects were excluded from the study and control populations: 1. women who experienced menarche less than 3 years prior to the start of the study; 2. women who received hormones, antioxidants or drugs for major medical diseases such as diabetes or cardiovascular disease; and 3. women who were older than 45.

Keywords: edcs pcos tas tos ros oxidative stress, endocrine-disrupting chemicals, polycystic ovary syndrome
efficacy of adding lidocaine 10% to phenol in ultrasound guided superior hypogastric plexus neurolysis in the management of pelvic cancer pain

Conditions: Efficacy of Adding Lidocaine 10% to Phenol in Superior Hypogastric Plexus Neurolysis

Summary: the superior hypogastric plexus (shp) is a complex nervous collection located at the lumbosacral region below the level of the aortic bifurcation at the level of the lower third of the fifth lumbar vertebral body and upper third of the first sacral vertebral body at the sacral promontory neurolytic agents, such as alcohol and phenol have been used to ablate peripheral nerves to treat pain and spasticity . these agents were nonspecific for neuronal tissue and complications have been seen involving damage to surrounding soft tissue (skin, muscle, vascular) and pain on alcohol injection lidocaine has been demonstrated to be neurotoxic in high concentrations at 10% and can be used as a neurolytic agent with no effect on motor function, muscle state, or surrounding tissue rather than other neurolytic.

every patient will be in supine trendelenburg position, iv access in case of adverse events and for moderate sedation if needed (for patient comfort, sever anxiety or needle phobia, or history of vagal events). the procedure will be completed under aseptic precautions. the division of abdominal aorta into common iliac arteries will be identified by using longitudinal sonography (lumify l12-4 linear array transducer 12 to 4 mhz extended operating frequency range, 34mm footprint and aperture size, and scan depth of up to 12cm. imaging modes include 2d, color doppler, and m-mode), and the body of the fifth (5th) lumbar vertebra will be identified by placing the transducer transversely. a skin wheal will be raised with subcutaneous infiltration with 2% lidocaine solution nearly 3-4 cm below the umbilicus. a 15-cm long 22-g chiba needle will be used with out of plane technique, and the needle will be advanced under usg-guidance to reach the anterior- most point of the fifth lumber vertebral body avoiding the vascular structures. the needle will be withdrawn nearly 1-2 mm after hitting the vertebral body to avoid injecting the drug into the periosteum. after confirming a negative aspiration of blood, known amount of neurolytic agent according to the grouping will be injected for the neurolysis of superior hypogastric plexus. the uniform spread of the drug will be confirmed under real-time sonography. vital sign parameters will be recorded during and after the procedure, during which patients remained fully awake

Eligibility criteria:
inclusion criteria: * patients more than 18 years old. * either genders. * cancer-related pelvic pain. * american society of anesthesiologists physical status class i and ii. * patients receiving opioids for pelvic cancer pain with visual analogue pain scale more than 4. * bmi \< 30. exclusion criteria: * . patient refusal. local or systemic sepsis. coagulopathy. unstable cardiovascular and respiratory diseases. previous neurological deficits, history of psychiatric disorders history of drug abuse distorted local anatomy. allergy to the used medications.
virtual reality training intervention on cognitive function and quality of life

Conditions: Virtual Reality; Cognitive Impairment; Quality of Life

Summary: the present study aimed to investigate the effects of a virtual reality cognitive training intervention (vrcti) on cognitive function changes measured with a cognitive test battery and improvement of quality of life in older adults with cognitive impairment in long-term care facilities. weekly 1-hour sessions were implemented over 8 weeks targeting sustained and selective attention, memory, cognitive functions, and rule deduction. the passive control group received usual care.

objectives: the present study aimed to investigate the effects of a virtual reality cognitive training intervention (vrcti) on cognitive function changes measured with a cognitive test battery and improvement of quality of life in older adults with cognitive impairment in long-term care facilities. method: weekly 1-hour sessions were implemented over 8 weeks targeting sustained and selective attention, memory, cognitive functions, and rule deduction. the vrcti comprised 12 different tasks distributed in 8 sessions with different difficulty levels. the passive control group received usual care. older adults were randomly assigned to either vr or control groups. an experimental pre-post design was used. accuracy, error, and repetition rates were measured throughout each session. intervention effects were analyzed using a generalized estimating equation model.

Eligibility criteria:
inclusion criteria: * aged ≥ 65 years * admitted as residents at the study-site institutions (long-term care facilities) * mini mental status examination (mmse) ≥ 13 * able to communicate sufficiently exclusion criteria: * open facial wounds * problems with a finger, hand, or wrist and/or major visual or auditory impairment, making it difficult to deliver training scheme * major neurological or psychiatric conditions that may affect cognition (e.g., stroke, dizziness, schizophrenia) * unstable medical conditions * were unable to comply with the intervention

Keywords: virtual reality cognitive impairment quality of life long-term care facilities
high flow nasal cannula in thoracic surgery: a physiologic study

Conditions: Thoracic Surgery; Respiratory Failure

Summary: the goal of this study is to evaluate the role that high-flow nasal cannulas (hfnc) have on respiratory drive, work of breathing and neuromuscular efficiency after lung resection surgery. the main question the investigators aim to answer is whether hfnc decrease respiratory drive by at least 15% in these patients, assessed by a special diaphragmatic electromyography (emg) device (nava catheter). in order, to perform this study, the investigators will perform a physiological study in 40 patients. these patients will be assessed in the immediate postoperative period and hfnc will be compared to conventional face-mask therapy.

single centre, physiological crossover clinical trial in 40 patients in the immediate postoperative period after lung resection, equipped with a nava catheter to monitor diaphragm electrical activity (eadi) and assess the effects that hfnc have on the respiratory drive and work of breathing as compared to conventional facemask oxygen therapy. once in the postoperative care unit (pacu) and 1) after recovery from anaesthesia, 2) cardiorespiratory stable and 3) pain-free (see below), the intervention will start. the study will assess the effect of hfnc and oxygen via face mask on eadi and diaphragm function, as measured by ultrasonography. hfnc and oxygen via face mask order will be randomized in a sequence (a-b or b-a) with the aid of a website (www.randomization.com). each intervention will last for 30 minutes. the oxygen-inspired fraction (fio2) will be adjusted to maintain a pulse oximetry (spo2) between \>92%. in the case of the high-flow nasal cannula, the study will be carried out with a flow of 50 l/min. eadi signal will be continuously monitored and its signal later exported to a laptop for further analysis. at the end of the 30-minute period, a blood sample will be obtained for gas analysis from the arterial line and the investigators will perform a diaphragm ultrasonography. ultrasonography will consist of measurement of diaphragm thickness and thickening on the right side during quiet breathing and diaphragmatic excursion on both sides.

Eligibility criteria:
inclusion criteria: * subjects submitted to lung resection with an expected mechanical ventilation time of more than 180 minutes. exclusion criteria: * patient refusal to participate * contraindications to nasogastric tube placement (i.e. oesophageal varices) * patients less than 18 years old * pregnancy * neuromuscular disease * prior thoracic surgery
an observational analysis of voriconazole therapeutic drug concentration monitoring, pharmacogenomics and clinical outcome correlations in high-risk hematology patients

Conditions: Acute Leukemia

Summary: hematology patients are at high risk for invasive fungal infection (ifi) and are being treated with voriconazole (vor) at princess margaret hospital (pmh). it is critical that patients' serum drug levels are within therapeutic ranges when undergoing treatment. the primary objective of this study is to determine whether clinical responses (complete/partial/failure) directly correlate with patients' blood vor drug levels. in patients whose disease progression is associated with inadequate voriconazole (vor) drug levels, serum drug level determination can allow for dose adjustment, thereby preventing disease progression. patients who are extensive metabolizers may have subtherapeutic vor levels leading to treatment failure whereas, poor metabolizers may have high drug levels that cause toxicity. isoenzyme such as cyp2c19 exhibits genetic polymorphism. genotyping tests can also be helpful in determining patient risk subjecting to extreme spectrum of drug levels.


Eligibility criteria:
inclusion criteria: * acute leukemia (including myelogenous and lymphocytic) patients for remission induction chemotherapy, reinduction chemotherapy and consolidation chemotherapy whose antifungal treatment include voriconazole. * patients have been subscribed voriconazole for probable or proven fungal infections by microbiological/cytohistological evidence from fine needle aspirate or bronchoalveolarlavage means. * patients will also have imaging positive from lose dose ct results depicting halo signs or crescent signs suggestive of invasive fungal infections. * patients must be able to tolerate oral intake of medications. exclusion criteria: * patients unable to tolerate oral administration with any combinations of severe mucositis (\> or = grade 3), nausea/vomiting (\> or = grade 3), diarrhea (\> or =grade 2), neutropenic enterocolitis (\> or = grade3).
an diagnostic cohort on aqp4-immunoglobulin g detection kit

Conditions: Neuromyelitis Optica Spectrum Disorders

Summary: the diagnostic cohort study could will be use to verify the clinical performance of the aqp4 -immunoglobulin g detection kit and whether it has a good correlation with the clinical diagnosis results. the applicability and accuracy of the kit in clinical diagnosis will be verified according to the measured data.


Eligibility criteria:
inclusion criteria: 1. the patients who were diagnosed with nmosd , and the cell-based assay was used to determine the aqp4-igg-seropositive patients; 2. aqp4-igg is negative in health people with age and sex matching and determined by cell-based assay; 3. female or male, age 14-80; 4. patients or authorized family members volunteered to participate in this study and signed informed consent. exclusion criteria: 1. patients with coagulation disorders; 2. infection-related encephalitis; 3. immune-related encephalitis; 4. a patient with severe mental illness who cannot cooperate clinically; 5. a patient with severe jaundice.
short-term efficacy of antidepressant in patients underwent tka

Conditions: Osteoarthritis Of Knee

Summary: by taking certain antidepressant in early postoperative period，which is supposed to improve the psychological status of patients with osteoarthritis, explore the effect of certain antidepressant on the recovery of the early stage after the operation of knee joint replacement.

in this study, the investigators are going to investigate the efficacy of duloxetine on pain, physical function, mental health and quality of life in patients underwent tkas. the control group is going to be given celecoxib 200mg/24h to 2 weeks after operation.on the basis of the above scheme, the treatment group is going to receiving duloxetine 60mg/24h to 8 weeks after operation.hamd-17 scale, kss scale, sf-36 scale and womac scale will be used to evaluate the two groups before and after operation for 4 and 8 weeks.

Eligibility criteria:
inclusion criteria: 1. no extra articular malformations are diagnosed and accord with kellgren-lawrence criteria 2. primary tka surgery,varus is smaller than 20° 3. always there is no history of mental illness, no history of relevant medicine 4. be able to read and understand chinese, with good communication skills 5. voluntary participation in this clinical study exclusion criteria: 1. previous history of mental and psychological illness 2. with severe diseases in respiratory system, circulatory system or digestive system 3. allergic to duloxetine and celecoxib

Keywords: osteoarthritis depression pain